Global X - Genomics & Biotechnology UCITS ETF
GNOG.L
London Stock Exchange- -
GBP
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- 10 Earlsfort Terrace Dublin Ireland D02 T380
- IPO Date
- Nov 2, 2021
- Website
- globalxetfs.eu
- Similar Companies
- Business
- Global X Genomics & Biotechnology UCITS ETF (GNOG.L) is an exchange-traded fund that seeks to correspond to the price and yield performance, before fees and expenses, of the Solactive Genomics & Biotechnology Index. The ETF provides exposure to companies positioned to benefit from advances in genomic sciences and biotechnology, including gene editing, genomic sequencing, genetic medicine and therapy, computational genomics, and related biotechnology tools and services; it invests across global markets with a focus on healthcare sector equities, predominantly in the United States (approximately 88%), Europe (around 9%), and smaller allocations to the United Kingdom and Asia. Top holdings include Alnylam Pharmaceuticals Inc., CRISPR Therapeutics AG, Avidity Biosciences Inc., Guardant Health Inc., and Arrowhead Pharmaceuticals Inc., representing about 26% of the portfolio; the fund is accumulating, fully replicating the index, with an ongoing charge of 0.50% and total assets under management of approximately GBP 14 million. Launched on 2 November 2021 and domiciled in Ireland with ISIN IE00BM8R0N95, the ETF trades on the London Stock Exchange and other European exchanges including those in Austria, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland, and the United Kingdom. In April 2025, the underlying Solactive Genomics & Biotechnology Index underwent a methodology change effective 1 April 2025, expanding the number of constituents from 40 to 50, incorporating pre-revenue and diversified companies while capping diversified players at 10% aggregate weight with a 2% individual limit to enhance thematic coverage; this adjustment aims to better reflect evolving industry trends in genomics. The ETF is issued by Global X ETFs ICAV, a specialist in thematic ETFs managed from its headquarters at 605 Third Avenue, 43rd Floor, New York, NY 10158, USA.